Palvella Therapeutics (PVLA) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2023)
Palvella Therapeutics (PVLA) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -9.89% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 21.04% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.71% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 411.50% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -7.63% |
| Mar 31, 2023 | -6.36% |
| Dec 31, 2022 | -4.49% |
| Sep 30, 2022 | 13.03% |
| Jun 30, 2022 | 30.25% |
| Mar 31, 2022 | 56.76% |
| Dec 31, 2021 | 55.87% |
| Sep 30, 2021 | 61.14% |
| Jun 30, 2021 | 64.26% |
| Mar 31, 2021 | 66.49% |
| Dec 31, 2020 | 76.14% |
| Sep 30, 2020 | 83.63% |
| Jun 30, 2020 | 88.02% |
| Mar 31, 2020 | 89.43% |
| Dec 31, 2019 | 104.99% |
| Sep 30, 2019 | 65.06% |
| Jun 30, 2019 | 47.72% |
| Mar 31, 2019 | 30.33% |
| Dec 31, 2018 | 32.66% |
| Sep 30, 2018 | 34.46% |